Phytochemicals as chemosensitizers: from molecular mechanism to clinical significance

Antioxidants and Redox Signaling

Volumn 18, Issue 11, 2013, Pages 1307-1348

  Vinod, Balachandran S ^a   Maliekal, Tessy Thomas ^a   Anto, Ruby John ^a  

^a RAJIV GANDHI CENTRE FOR BIOTECHNOLOGY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

(6) GINGEROL; ALKYLATING AGENT; ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; APIGENIN; BIOCHANIN A; CAFFEIC ACID; CAPSAICIN; CURCUMIN; DAIDZEIN; DEATH RECEPTOR; DNA; DOXORUBICIN; EMODIN; EPICATECHIN; EPIGALLOCATECHIN GALLATE; GALLIC ACID; GENISTEIN; MULTIDRUG RESISTANCE PROTEIN; MYRICETIN; PHENOL DERIVATIVE; PIPERINE; PLANT MEDICINAL PRODUCT; POLYPHENON E; QUERCETIN; RESVERATROL; SILIBININ; SILYMARIN; TANNIN; UNINDEXED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; AUTOPHAGY; B CELL LYMPHOMA; BLADDER CANCER; CANCER CELL; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CELL CYCLE ARREST; CELL DEATH; CELL KILLING; CELL PROLIFERATION; CELL SURVIVAL; CHEMOPROPHYLAXIS; CHEMOSENSITIZATION; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL (TOPIC); COLON CANCER; COLORECTAL CANCER; CYTOTOXICITY; DNA REPAIR; DRUG EFFICACY; DRUG MECHANISM; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LUNG NON SMALL CELL CANCER; MEDIATOR; MESOTHELIOMA; MULTIPLE MYELOMA; NEOPLASM; NONHUMAN; OSTEOSARCOMA; PANCREAS CANCER; PHYTOCHEMISTRY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE CARCINOMA; PROTEIN EXPRESSION; PROTEIN FUNCTION; RECEPTOR DOWN REGULATION; REVIEW; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; DRUG RESISTANCE; HUMANS; NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 84874454497     PISSN: 15230864     EISSN: 15577716     Source Type: Journal    
DOI: 10.1089/ars.2012.4573     Document Type: Review

References (336)

1. Adhikari S, Choudhury S, Mitra PS, Dubash JJ, Sajankila SP, and Roy R. Targeting base excision repair for chemosensitization. Anticancer Agents Med Chem 8: 351-357, 2008.
2. Aggarwal BB, Shishodia S, Takada Y, Banerjee S, Newman RA, Bueso-Ramos CE, and Price JE. Curcumin suppresses the paclitaxel-induced nuclear factor-kappaB pathway in breast cancer cells and inhibits lung metastasis of human breast cancer in nude mice. Clin Cancer Res 11: 7490-7498, 2005.
3. Ahmad KA, Clement MV, Hanif IM, and Pervaiz S. Resveratrol inhibits drug-induced apoptosis in human leukemia cells by creating an intracellular milieu nonpermissive for death execution. Cancer Res 64: 1452-1459, 2004.
4. Ajabnoor GM, Crook T, and Coley HM. Paclitaxel resistance is associated with switch from apoptotic to autophagic cell death in MCF-7 breast cancer cells. Cell Death Dis 3: E260, 2012.
5. Almeida L, Vaz-da-Silva M, Falcao A, Soares E, Costa R, Loureiro AI, Fernandes-Lopes C, Rocha JF, Nunes T, Wright L, and Soares-da-Silva P. Pharmacokinetic and safety profile of trans-resveratrol in a rising multiple-dose study in healthy volunteers. Mol Nutr Food Res 53 Suppl 1: S7-S15, 2009.
6. Anand P, Kunnumakkara AB, Newman RA, and Aggarwal BB. Bioavailability of curcumin: problems and promises. Mol Pharm 4: 807-818, 2007.
7. Anand P, Nair HB, Sung B, Kunnumakkara AB, Yadav VR, Tekmal RR, and Aggarwal BB. Design of curcumin-loaded PLGA nanoparticles formulation with enhanced cellular uptake, and increased bioactivity in vitro and superior bioavailability in vivo. Biochem Pharmacol 79: 330-338, 2010.
8. Anuchapreeda S, Leechanachai P, Smith MM, Ambudkar SV, and Limtrakul PN. Modulation of P-glycoprotein expression and function by curcumin in multidrug-resistant human KB cells. Biochem Pharmacol 64: 573-582, 2002.
9. Aravindan N, Veeraraghavan J, Madhusoodhanan R, Herman TS, and Natarajan M. Curcumin regulates lowlinear energy transfer gamma-radiation-induced NFkappaB-dependent telomerase activity in human neuroblastoma cells. Int J Radiat Oncol Biol Phys 79: 1206-1215, 2011.
10. Arlt A, Gehrz A, Muerkoster S, Vorndamm J, Kruse ML, Folsch UR, and Schafer H. Role of NF-kappaB and Akt/PI3K in the resistance of pancreatic carcinoma cell lines against gemcitabine-induced cell death. Oncogene 22: 3243-3251, 2003.
11. Avril MF, Aamdal S, Grob JJ, Hauschild A, Mohr P, Bonerandi JJ, Weichenthal M, Neuber K, Bieber T, Gilde K, Guillem Porta V, Fra J, Bonneterre J, Saiag P, Kamanabrou D, Pehamberger H, Sufliarsky J, Gonzalez Larriba JL, Scherrer A, and Menu Y. Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: A phase III study. J Clin Oncol 22: 1118-1125, 2004.
12. Awasthi N, Schwarz MA, and Schwarz RE. Proteasome inhibition enhances antitumour effects of gemcitabine in experimental pancreatic cancer. HPB (Oxford) 11: 600-605, 2009.
13. Banerjee M, Singh P, and Panda D. Curcumin suppresses the dynamic instability of microtubules, activates the mitotic checkpoint and induces apoptosis in MCF-7 cells. FEBS J 277: 3437-3448, 2010.
14. Banerjee S, Zhang Y, Ali S, Bhuiyan M, Wang Z, Chiao PJ, Philip PA, Abbruzzese J, and Sarkar FH. Molecular evidence for increased antitumor activity of gemcitabine by genistein in vitro and in vivo using an orthotopic model of pancreatic cancer. Cancer Res 65: 9064-9072, 2005.
15. Banerjee S, Zhang Y, Wang Z, Che M, Chiao PJ, Abbruzzese JL, and Sarkar FH. In vitro and in vivo molecular evidence of genistein action in augmenting the efficacy of cisplatin in pancreatic cancer. Int J Cancer 120: 906-917, 2007.
16. Bao L, Haque A, Jackson K, Hazari S, Moroz K, Jetly R, and Dash S. Increased expression of P-glycoprotein is associated with doxorubicin chemoresistance in the metastatic 4T1 breast cancer model. Am J Pathol 178: 838-852, 2011.
17. Bava SV, Puliappadamba VT, Deepti A, Nair A, Karunagaran D, and Anto RJ. Sensitization of taxol-induced apoptosis by curcumin involves down-regulation of nuclear factor-kappaB and the serine/threonine kinase Akt and is independent of tubulin polymerization. J Biol Chem 280: 6301-6308, 2005.
18. Bava SV, Sreekanth CN, Thulasidasan AK, Anto NP, Cheriyan VT, Puliyappadamba VT, Menon SG, Ravichandran SD, and Anto RJ. Akt is upstream and MAPKs are downstream of NF-kappaB in paclitaxel-induced survival signaling events, which are down-regulated by curcumin contributing to their synergism. Int J Biochem Cell Biol 43: 331-341, 2010.
19. Bayet-Robert M, Kwiatkowski F, Leheurteur M, Gachon F, Planchat E, Abrial C, Mouret-Reynier MA, Durando X, Barthomeuf C, and Chollet P. Phase I dose escalation trial of docetaxel plus curcumin in patients with advanced and metastatic breast cancer. Cancer Biol Ther 9: 8-14, 2010.
20. Bettuzzi S, Brausi M, Rizzi F, Castagnetti G, Peracchia G, and Corti A. Chemoprevention of human prostate cancer by oral administration of green tea catechins in volunteers with high-grade prostate intraepithelial neoplasia: A preliminary report from a one-year proof-of-principle study. Cancer Res 66: 1234-1240, 2006.
21. Bhardwaj A, Sethi G, Vadhan-Raj S, Bueso-Ramos C, Takada Y, Gaur U, Nair AS, Shishodia S, and Aggarwal BB. Resveratrol inhibits proliferation, induces apoptosis, and overcomes chemoresistance through down-regulation of STAT3 and nuclear factor-kappaB-regulated antiapoptotic and cell survival gene products in human multiple myeloma cells. Blood 109: 2293-2302, 2007.
22. Bharti AC, Donato N, Singh S, and Aggarwal BB. Curcumin (diferuloylmethane) down-regulates the constitutive activation of nuclear factor-kappa B and IkappaBalpha kinase in human multiple myeloma cells, leading to suppression of proliferation and induction of apoptosis. Blood 101: 1053-1062, 2003.
23. Bianco R, Ciardiello F, and Tortora G. Chemosensitization by antisense oligonucleotides targeting MDM2. Curr Cancer Drug Targets 5: 51-56, 2005.
24. Bobe G, Albert PS, Sansbury LB, Lanza E, Schatzkin A, Colburn NH, and Cross AJ. Interleukin-6 as a potential indicator for prevention of high-risk adenoma recurrence by dietary flavonols in the polyp prevention trial. Cancer Prev Res (Phila) 3: 764-775, 2010.
25. Boocock DJ, Faust GE, Patel KR, Schinas AM, Brown VA, Ducharme MP, Booth TD, Crowell JA, Perloff M, Gescher AJ, Steward WP, and Brenner DE. Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent. Cancer Epidemiol Biomarkers Prev 16: 1246-1252, 2007.
26. Brown AL, Lane J, Holyoak C, Nicol B, Mayes AE, and Dadd T. Health effects of green tea catechins in overweight and obese men: A randomised controlled cross-over trial. Br J Nutr 106: 1880-1889, 2011.
27. Brown VA, Patel KR, Viskaduraki M, Crowell JA, Perloff M, Booth TD, Vasilinin G, Sen A, Schinas AM, Piccirilli G, Brown K, Steward WP, Gescher AJ, and Brenner DE. Repeat dose study of the cancer chemopreventive agent resveratrol in healthy volunteers: safety, pharmacokinetics, and effect on the insulin-like growth factor axis. Cancer Res 70: 9003-9011, 2010.
28. Bruning A, Vogel M, Mylonas I, Friese K, and Burges A. Bortezomib targets the caspase-like proteasome activity in cervical cancer cells, triggering apoptosis that can be enhanced by nelfinavir. Curr Cancer Drug Targets 11: 799-809, 2011.
29. Cai J, Niu X, Chen Y, Hu Q, Shi G, Wu H, Wang J, and Yi J. Emodin-induced generation of reactive oxygen species inhibits RhoA activation to sensitize gastric carcinoma cells to anoikis. Neoplasia 10: 41-51, 2008.
30. Campos-Arroyo D, Martinez-Lazcano JC, and Melendez-Zajgla J. Probenecid is a chemosensitizer in cancer cell lines. Cancer Chemother Pharmacol 69: 495-504, 2012.
31. Castino R, Peracchio C, Salini A, Nicotra G, Trincheri NF, Demoz M, Valente G, and Isidoro C. Chemotherapy drug response in ovarian cancer cells strictly depends on a cathepsin D-Bax activation loop. J Cell MolMed 13: 1096-1109, 2009.
32. Cervi D, Truong AH, Lee JS, Sukhai N, Li YJ, Koki A, and Ben-David Y. Phosphorylation status of c-Kit and Epo receptors, and the presence of wild-type p53 confer in vitro resistance of murine erythroleukemic cells to Celecoxib. Oncogene 23: 2305-2314, 2004.
33. Chakraborty S, Stalin S, Das N, Choudhury ST, Ghosh S, and Swarnakar S. The use of nano-quercetin to arrest mitochondrial damage and MMP-9 upregulation during prevention of gastric inflammation induced by ethanol in rat. Biomaterials 33: 2991-3001, 2012.
34. Chan MM, Fong D, Soprano KJ, Holmes WF, and Heverling H. Inhibition of growth and sensitization to cisplatinmediated killing of ovarian cancer cells by polyphenolic chemopreventive agents. J Cell Physiol 194: 63-70, 2003.
35. Chang Q, Liu ZR, Wang DY, Kumar M, Chen YB, and Qin RY. Survivin expression induced by doxorubicin in cholangiocarcinoma. World J Gastroenterol 10: 415-418, 2004.
36. Chapman PB, Einhorn LH, Meyers ML, Saxman S, Destro AN, Panageas KS, Begg CB, Agarwala SS, Schuchter LM, Ernstoff MS, Houghton AN, and Kirkwood JM. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol 17: 2745-2751, 1999.
37. Chen C, Zhou J, and Ji C. Quercetin: A potential drug to reverse multidrug resistance. Life Sci 87: 333-338, 2010.
38. Chen J, Jin S, Abraham V, Huang X, Liu B, Mitten MJ, Nimmer P, Lin X, Smith M, Shen Y, Shoemaker AR, Tahir SK, Zhang H, Ackler SL, Rosenberg SH, Maecker H, Sampath D, Leverson JD, Tse C, and Elmore SW. The Bcl-2/Bcl-X(L)/Bcl-w inhibitor, navitoclax, enhances the activity of chemotherapeutic agents in vitro and in vivo. Mol Cancer Ther 10: 2340-2349, 2011.
39. Chen J, Kobayashi M, Darmanin S, Qiao Y, Gully C, Zhao R, Yeung SC, and Lee MH. Pim-1 plays a pivotal role in hypoxiainduced chemoresistance. Oncogene 28: 2581-2592, 2009.
40. Chen M, Zou X, Luo H, Cao J, Zhang X, Zhang B, and Liu W. Effects and mechanisms of proton pump inhibitors as a novel chemosensitizer on human gastric adenocarcinoma (SGC7901) cells. Cell Biol Int 33: 1008-1019, 2009.
41. Chen RS, Jhan JY, Su YJ, Lee WT, Cheng CM, Ciou SC, Lin ST, Chuang SM, Ko JC, and Lin YW. Emodin enhances gefitinib-induced cytotoxicity via Rad51 downregulation and ERK1/2 inactivation. Exp Cell Res 315: 2658-2672, 2009.
42. Chen W, Wang X, Zhuang J, Zhang L, and Lin Y. Induction of death receptor 5 and suppression of survivin contribute to sensitization of TRAIL-induced cytotoxicity by quercetin in non-small cell lung cancer cells. Carcinogenesis 28: 2114-2121, 2007.
43. Cheng AL, Hsu CH, Lin JK, Hsu MM, Ho YF, Shen TS, Ko JY, Lin JT, Lin BR, Ming-Shiang W, Yu HS, Jee SH, Chen GS, Chen TM, Chen CA, Lai MK, Pu YS, Pan MH, Wang YJ, Tsai CC, and Hsieh CY. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or premalignant lesions. Anticancer Res 21: 2895-2900, 2001.
44. Chidambaram M, Manavalan R, and Kathiresan K. Nanotherapeutics to overcome conventional cancer chemotherapy limitations. J Pharm Pharm Sci 14: 67-77, 2011.
45. Chirnomas D, Taniguchi T, de la Vega M, Vaidya AP, Vasserman M, Hartman AR, Kennedy R, Foster R, Mahoney J, Seiden MV, and D'Andrea AD. Chemosensitization to cisplatin by inhibitors of the Fanconi anemia/BRCA pathway. Mol Cancer Ther 5: 952-961, 2006.
46. Chisholm K, Bray BJ, and Rosengren RJ. Tamoxifen and epigallocatechin gallate are synergistically cytotoxic to MDA-MB-231 human breast cancer cells. Anticancer Drugs 15: 889-897, 2004.
47. Choan E, Segal R, Jonker D, Malone S, Reaume N, Eapen L, and Gallant V. A prospective clinical trial of green tea for hormone refractory prostate cancer: An evaluation of the complementary/alternative therapy approach. Urol Oncol 23: 108-113, 2005.
48. Chow HH, Cai Y, Alberts DS, Hakim I, Dorr R, Shahi F, Crowell JA, Yang CS, and Hara Y. Phase I pharmacokinetic study of tea polyphenols following single-dose administration of epigallocatechin gallate and polyphenon E. Cancer Epidemiol Biomarkers Prev 10: 53-58, 2001.
49. Chow HH, Garland LL, Hsu CH, Vining DR, Chew WM, Miller JA, Perloff M, Crowell JA, and Alberts DS. Resveratrol modulates drug- and carcinogen- metabolizing enzymes in a healthy volunteer study. Cancer Prev Res (Phila) 3: 1168-1175, 2010.
50. Clark AS, West K, Streicher S, and Dennis PA. Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells. Mol Cancer Ther 1: 707-717, 2002.
51. Cohen R, Schwartz B, Peri I, and Shimoni E. Improving bioavailability and stability of genistein by complexation with high-amylose corn starch. J Agric Food Chem 59: 7932-7938, 2011.
52. Cole SP and Deeley RG. Multidrug resistance mediated by the ATP-binding cassette transporter protein MRP. Bioessays 20: 931-940, 1998.
53. Colin D, Gimazane A, Lizard G, Izard JC, Solary E, Latruffe N, and Delmas D. Effects of resveratrol analogs on cell cycle progression, cell cycle associated proteins and 5fluoro-uracil sensitivity in human derived colon cancer cells. Int J Cancer 124: 2780-2788, 2009.
54. Condorelli G, Vigliotta G, Cafieri A, Trencia A, Andalo P, Oriente F, Miele C, Caruso M, Formisano P, and Beguinot F. PED/PEA-15: An anti-apoptotic molecule that regulates FAS/TNFR1-induced apoptosis. Oncogene 18: 4409-4415, 1999.
55. Conklin KA. Cancer chemotherapy and antioxidants. J Nutr 134: 3201SY3204S, 2004.
56. Critchfield JW, Welsh CJ, Phang JM, and Yeh GC. Modulation of adriamycin accumulation and efflux by flavonoids in HCT-15 colon cells. Activation of P-glycoprotein as a putative mechanism. Biochem Pharmacol 48: 1437-1445, 1994.
57. Cruz-Correa M, Shoskes DA, Sanchez P, Zhao R, Hylind LM, Wexner SD, and Giardiello FM. Combination treatment with curcumin and quercetin of adenomas in familial adenomatous polyposis. Clin Gastroenterol Hepatol 4: 1035-1038, 2006.
58. Cummins JM, Kohli M, Rago C, Kinzler KW, Vogelstein B, and Bunz F. X-linked inhibitor of apoptosis protein (XIAP) is a nonredundant modulator of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis in human cancer cells. Cancer Res 64: 3006-3008, 2004.
59. Dai Q, Shu XO, Jin F, Potter JD, Kushi LH, Teas J, Gao YT, and Zheng W. Population-based case-control study of soyfood intake and breast cancer risk in Shanghai. Br J Cancer 85: 372-378, 2001.
60. Dalton WS, Crowley JJ, Salmon SS, Grogan TM, Laufman LR, Weiss GR, and Bonnet JD. A phase III randomized study of oral verapamil as a chemosensitizer to reverse drug resistance in patients with refractory myeloma. A Southwest Oncology Group study. Cancer 75: 815-820, 1995.
61. Davis TA, Mungunsukh O, Zins S, Day RM, and Landauer MR. Genistein induces radioprotection by hematopoietic stem cell quiescence. Int J Radiat Biol 84: 713-726, 2008.
62. De Laurentiis M, Arpino G, Massarelli E, Ruggiero A, Carlomagno C, Ciardiello F, Tortora G, D'Agostino D, Caputo F, Cancello G, Montagna E, Malorni L, Zinno L, Lauria R, Bianco AR, and De Placido S. A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer. Clin Cancer Res 11: 4741-4748, 2005.
63. Deeb D, Jiang H, Gao X, Al-Holou S, Danyluk AL, Dulchavsky SA, and Gautam SC. Curcumin [1,7-bis(4-hydroxy-3-methoxyphenyl)-1-6-heptadine-3,5-dione; C21H20O6] sensitizes human prostate cancer cells to tumor necrosis factor-related apoptosis-inducing ligand/Apo2L-induced apoptosis by suppressing nuclear factor-kappaB via inhibition of the prosurvival Akt signaling pathway. J Pharmacol Exp Ther 321: 616-625, 2007.
64. Deeb D, Jiang H, Gao X, Hafner MS, Wong H, Divine G, Chapman RA, Dulchavsky SA, and Gautam SC. Curcumin sensitizes prostate cancer cells to tumor necrosis factorrelated apoptosis-inducing ligand/Apo2L by inhibiting nuclear factor-kappaB through suppression of IkappaBalpha phosphorylation. Mol Cancer Ther 3: 803-812, 2004.
65. deGraffenried LA, Chandrasekar B, Friedrichs WE, Donzis E, Silva J, Hidalgo M, Freeman JW, and Weiss GR. NFkappa B inhibition markedly enhances sensitivity of resistant breast cancer tumor cells to tamoxifen. Ann Oncol 15: 885-890, 2004.
66. Delmas D, Rebe C, Micheau O, Athias A, Gambert P, Grazide S, Laurent G, Latruffe N, and Solary E. Redistribution of CD95, DR4 and DR5 in rafts accounts for the synergistic toxicity of resveratrol and death receptor ligands in colon carcinoma cells. Oncogene 23: 8979-8986, 2004.
67. deVere White RW, Hackman RM, Soares SE, Beckett LA, Li Y, and Sun B. Effects of a genistein-rich extract on PSA levels in men with a history of prostate cancer. Urology 63: 259-263, 2004.
68. Dhillon N, Aggarwal BB, Newman RA, Wolff RA, Kunnumakkara AB, Abbruzzese JL, Ng CS, Badmaev V, and Kurzrock R. Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin Cancer Res 14: 4491-4499, 2008.
69. Domagk D, Bluthner-Hassler C, Kugler A, Kallerhoff M, and Ringert RH. Influence of vinblastine on DNA parameters and multidrug resistance in renal cell carcinoma in vitro. Urol Res 26: 123-127, 1998.
70. Doyle LA, Yang W, Abruzzo LV, Krogmann T, Gao Y, Rishi AK, and Ross DD. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci U S A 95: 15665-15670, 1998.
71. Du B, Jiang L, Xia Q, and Zhong L. Synergistic inhibitory effects of curcumin and 5-fluorouracil on the growth of the human colon cancer cell line HT-29. Chemotherapy 52: 23-28, 2006.
72. Du G, Lin H, Wang M, Zhang S, Wu X, Lu L, Ji L, and Yu L. Quercetin greatly improved therapeutic index of doxorubicin against 4T1 breast cancer by its opposing effects on HIF-1alpha in tumor and normal cells. Cancer Chemother Pharmacol 65: 277-287, 2010.
73. Du G, Lin H, Yang Y, Zhang S, Wu X, Wang M, Ji L, Lu L, Yu L, and Han G. Dietary quercetin combining intratumoral doxorubicin injection synergistically induces rejection of established breast cancer in mice. Int Immunopharmacol 10: 819-826, 2010.
74. Du M, Yang X, Hartman JA, Cooke PS, Doerge DR, Ju YH, and Helferich WG. Low-dose dietary genistein negates the therapeutic effect of tamoxifen in athymic nude mice. Carcinogenesis 33: 895-901, 2012.
75. El-Deiry WS. The role of p53 in chemosensitivity and radiosensitivity. Oncogene 22: 7486-7495, 2003.
76. El-Rayes BF, Ali S, Ali IF, Philip PA, Abbruzzese J, and Sarkar FH. Potentiation of the effect of erlotinib by genistein in pancreatic cancer: The role of Akt and nuclear factorkappaB. Cancer Res 66: 10553-10559, 2006.
77. El-Rayes BF, Philip PA, Sarkar FH, Shields AF, Ferris AM, Hess K, Kaseb AO, Javle MM, Varadhachary GR, Wolff RA, and Abbruzzese JL. A phase II study of isoflavones, erlotinib, and gemcitabine in advanced pancreatic cancer. Invest New Drugs 29: 694-699, 2011.
78. Elder DJ and Paraskeva C. COX-2 inhibitors for colorectal cancer. Nat Med 4: 392-393, 1998.
79. Epelbaum R, Schaffer M, Vizel B, Badmaev V, and Bar-Sela G. Curcumin and gemcitabine in patients with advanced pancreatic cancer. Nutr Cancer 62: 1137-1141, 2010.
80. Ermakova SP, Kang BS, Choi BY, Choi HS, Schuster TF, Ma WY, Bode AM, and Dong Z. (-) -Epigallocatechin gallate overcomes resistance to etoposide-induced cell death by targeting the molecular chaperone glucose-regulated protein 78. Cancer Res 66: 9260-9269, 2006.
81. Farabegoli F, Papi A, Bartolini G, Ostan R, and Orlandi M. (-) -Epigallocatechin-3-gallate downregulates Pg-P and BCRP in a tamoxifen resistant MCF-7 cell line. Phytomedicine 17: 356-362, 2010.
82. Federico A, Morgillo F, Tuccillo C, Ciardiello F, and Loguercio C. Chronic inflammation and oxidative stress in human carcinogenesis. Int J Cancer 121: 2381-2386, 2007.
83. Ferry DR, Smith A, Malkhandi J, Fyfe DW, deTakats PG, Anderson D, Baker J, and Kerr DJ. Phase I clinical trial of the flavonoid quercetin: pharmacokinetics and evidence for in vivo tyrosine kinase inhibition. Clin Cancer Res 2: 659-668, 1996.
84. Frampton GA, Lazcano EA, Li H, Mohamad A, and De-Morrow S. Resveratrol enhances the sensitivity of cholangiocarcinoma to chemotherapeutic agents. Lab Invest 90: 1325-1338, 2010.
85. Fukui M, Yamabe N, and Zhu BT. Resveratrol attenuates the anticancer efficacy of paclitaxel in human breast cancer cells in vitro and in vivo. Eur J Cancer 46: 1882-1891, 2010.
86. Fulda S and Debatin KM. Resveratrol-mediated sensitisation to TRAIL-induced apoptosis depends on death receptor and mitochondrial signalling. Eur J Cancer 41: 786-798, 2005.
87. Fulda S and Debatin KM. Sensitization for anticancer druginduced apoptosis by the chemopreventive agent resveratrol. Oncogene 23: 6702-6711, 2004.
88. Fulda S, Meyer E, and Debatin KM. Inhibition of TRAILinduced apoptosis by Bcl-2 overexpression. Oncogene 21: 2283-2294, 2002.
89. Gandapu U, Chaitanya RK, Kishore G, Reddy RC, and Kondapi AK. Curcumin-loaded apotransferrin nanoparticles provide efficient cellular uptake and effectively inhibit HIV-1 replication in vitro. PLoS One 6: E23388, 2011.
90. Gandhi L, Camidge DR, Ribeiro de Oliveira M, Bonomi P, Gandara D, Khaira D, Hann CL, McKeegan EM, Litvinovich E, Hemken PM, Dive C, Enschede SH, Nolan C, Chiu YL, Busman T, Xiong H, Krivoshik AP, Humerickhouse R, Shapiro GI, and Rudin CM. Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors. J Clin Oncol 29: 909-916, 2011.
91. Garcea G, Berry DP, Jones DJ, Singh R, Dennison AR, Farmer PB, Sharma RA, Steward WP, and Gescher AJ. Consumption of the putative chemopreventive agent curcumin by cancer patients: Assessment of curcumin levels in the colorectum and their pharmacodynamic consequences. Cancer Epidemiol Biomarkers Prev 14: 120-125, 2005.
92. Garg AK, Hortobagyi GN, Aggarwal BB, Sahin AA, and Buchholz TA. Nuclear factor-kappa B as a predictor of treatment response in breast cancer. Curr Opin Oncol 15: 405-411, 2003.
93. Gerl R and Vaux DL. Apoptosis in the development and treatment of cancer. Carcinogenesis 26: 263-270, 2005.
94. Ghiringhelli F, Rebe C, Hichami A, and Delmas D. Immunomodulation and anti-inflammatory roles of polyphenols as anticancer agents. Anticancer Agents Med Chem 12: 852-873, 2012.
95. Guo Q, Chen Y, Zhang B, Kang M, Xie Q, and Wu Y. Potentiation of the effect of gemcitabine by emodin in pancreatic cancer is associated with survivin inhibition. Biochem Pharmacol 77: 1674-1683, 2009.
96. Guo X, Ma N, Wang J, Song J, Bu X, Cheng Y, Sun K, Xiong H, Jiang G, Zhang B, Wu M, and Wei L. Increased p38-MAPK is responsible for chemotherapy resistance in human gastric cancer cells. BMC Cancer 8: 375, 2008.
97. Guo XL, Li D, Hu F, Song JR, Zhang SS, Deng WJ, Sun K, Zhao QD, Xie XQ, Song YJ, Wu MC, and Wei LX. Targeting autophagy potentiates chemotherapy-induced apoptosis and proliferation inhibition in hepatocarcinoma cells. Cancer Lett 320: 171-179, 2012.
98. Gupta SC, Kannappan R, Reuter S, Kim JH, and Aggarwal BB. Chemosensitization of tumors by resveratrol. Ann N Y Acad Sci 1215: 150-160, 2011.
99. Harari D and Yarden Y. Molecular mechanisms underlying ErbB2/HER2 action in breast cancer. Oncogene 19: 6102-6114, 2000.
100. Harhaji L, Mijatovic S, Maksimovic-Ivanic D, Popadic D, Isakovic A, Todorovic-Markovic B, and Trajkovic V. Aloe emodin inhibits the cytotoxic action of tumor necrosis factor. Eur J Pharmacol 568: 248-259, 2007.
101. Harikumar KB, Kunnumakkara AB, Sethi G, Diagaradjane P, Anand P, Pandey MK, Gelovani J, Krishnan S, Guha S, and Aggarwal BB. Resveratrol, a multitargeted agent, can enhance antitumor activity of gemcitabine in vitro and in orthotopic mouse model of human pancreatic cancer. Int J Cancer 127: 257-268, 2010.
102. He ZY, Shi CB, Wen H, Li FL, Wang BL, and Wang J. Upregulation of p53 expression in patients with colorectal cancer by administration of curcumin. Cancer Invest 29: 208-213, 2011.
103. Henning SM, Aronson W, Niu Y, Conde F, Lee NH, Seeram NP, Lee RP, Lu J, Harris DM, Moro A, Hong J, Pak-Shan L, Barnard RJ, Ziaee HG, Csathy G, Go VL, Wang H, and Heber D. Tea polyphenols and theaflavins are present in prostate tissue of humans and mice after green and black tea consumption. J Nutr 136: 1839-1843, 2006.
104. Horvath Z, Saiko P, Illmer C, Madlener S, Hoechtl T, Bauer W, Erker T, Jaeger W, Fritzer-Szekeres M, and Szekeres T. Synergistic action of resveratrol, an ingredient of wine, with Ara-C and tiazofurin in HL-60 human promyelocytic leukemia cells. Exp Hematol 33: 329-335, 2005.
105. Hour TC, Chen J, Huang CY, Guan JY, Lu SH, and Pu YS. Curcumin enhances cytotoxicity of chemotherapeutic agents in prostate cancer cells by inducing p21(WAF1/CIP1) and C/EBPbeta expressions and suppressing NFkappaB activation. Prostate 51: 211-218, 2002.
106. Howells LM, Berry DP, Elliott PJ, Jacobson EW, Hoffmann E, Hegarty B, Brown K, Steward WP, and Gescher AJ. Phase I randomized, double-blind pilot study of micronized resveratrol (SRT501) in patients with hepatic metastases - safety, pharmacokinetics, and pharmacodynamics. Cancer Prev Res (Phila) 4: 1419-1425, 2011.
107. Hsieh DS, Wang H, Tan SW, Huang YH, Tsai CY, Yeh MK, and Wu CJ. The treatment of bladder cancer in a mouse model by epigallocatechin-3-gallate-gold nanoparticles. Biomaterials 32: 7633-7640, 2011.
108. Huang Q, Yu H, and Ru Q. Bioavailability and delivery of nutraceuticals using nanotechnology. J Food Sci 75: R50-R57, 2010.
109. Huang XZ, Wang J, Huang C, Chen YY, Shi GY, Hu QS, and Yi J. Emodin enhances cytotoxicity of chemotherapeutic drugs in prostate cancer cells: The mechanisms involve ROS-mediated suppression of multidrug resistance and hypoxia inducible factor-1. Cancer Biol Ther 7: 468-475, 2008.
110. Hwang JT, Ha J, Park IJ, Lee SK, Baik HW, Kim YM, and Park OJ. Apoptotic effect of EGCG in HT-29 colon cancer cells via AMPK signal pathway. Cancer Lett 247: 115-121, 2007.
111. Hwang JT, Ha J, and Park OJ. Combination of 5-fluorouracil and genistein induces apoptosis synergistically in chemo-resistant cancer cells through the modulation of AMPK and COX-2 signaling pathways. Biochem Biophys Res Commun 332: 433-440, 2005.
112. Igney FH and Krammer PH. Death and anti-death: Tumour resistance to apoptosis. Nat Rev Cancer 2: 277-288, 2002.
113. Ikeguchi M, Liu J, and Kaibara N. Expression of survivin mRNA and protein in gastric cancer cell line (MKN-45) during cisplatin treatment. Apoptosis 7: 23-29, 2002.
114. Ivanov VN, Partridge MA, Johnson GE, Huang SX, Zhou H, and Hei TK. Resveratrol sensitizes melanomas to TRAIL through modulation of antiapoptotic gene expression. Exp Cell Res 314: 1163-1176, 2008.
115. Jacquemont C, Simon JA, D'Andrea AD, and Taniguchi T. Non-specific chemical inhibition of the Fanconi anemia pathway sensitizes cancer cells to cisplatin. Mol Cancer 11: 26, 2012.
116. Jakubowicz-Gil J, Langner E, Wertel I, Piersiak T, and Rzeski W. Temozolomide, quercetin and cell death in the MOGGCCM astrocytoma cell line. Chem Biol Interact 188: 190-203, 2010.
117. Jakubowicz-Gil J, Paduch R, Piersiak T, Glowniak K, Gawron A, and Kandefer-Szerszen M. The effect of quercetin on pro-apoptotic activity of cisplatin in HeLa cells. Biochem Pharmacol 69: 1343-1350, 2005.
118. Jatoi A, Ellison N, Burch PA, Sloan JA, Dakhil SR, Novotny P, Tan W, Fitch TR, Rowland KM, Young CY, and Flynn PJ. A phase II trial of green tea in the treatment of patients with androgen independent metastatic prostate carcinoma. Cancer 97: 1442-1446, 2003.
119. Javvadi P, Hertan L, Kosoff R, Datta T, Kolev J, Mick R, Tuttle SW, and Koumenis C. Thioredoxin reductase-1 mediates curcumin-induced radiosensitization of squamous carcinoma cells. Cancer Res 70: 1941-1950, 2010.
120. Jazirehi AR and Bonavida B. Resveratrol modifies the expression of apoptotic regulatory proteins and sensitizes non-Hodgkin's lymphoma and multiple myeloma cell lines to paclitaxel-induced apoptosis. Mol Cancer Ther 3: 71-84, 2004.
121. Jeong JH, An JY, Kwon YT, Li LY, and Lee YJ. Quercetininduced ubiquitination and down-regulation of Her-2/neu. J Cell Biochem 105: 585-595, 2008.
122. Jian L, Xie LP, Lee AH, and Binns CW. Protective effect of green tea against prostate cancer: A case-control study in southeast China. Int J Cancer 108: 130-135, 2004.
123. Jin CY, Park C, Cheong J, Choi BT, Lee TH, Lee JD, Lee WH, Kim GY, Ryu CH, and Choi YH. Genistein sensitizes TRAIL-resistant human gastric adenocarcinoma AGS cells through activation of caspase-3. Cancer Lett 257: 56-64, 2007.
124. Jin CY, Park C, Kim GY, Lee SJ, Kim WJ, and Choi YH. Genistein enhances TRAIL-induced apoptosis through inhibition of p38 MAPK signaling in human hepatocellular carcinoma Hep3B cells. Chem Biol Interact 180: 143-150, 2009.
125. Jin HS, Lee DH, Kim DH, Chung JH, Lee SJ, and Lee TH. cIAP1, cIAP2, and XIAP act cooperatively via nonredundant pathways to regulate genotoxic stress-induced nuclear factor-kappaB activation. Cancer Res 69: 1782-1791, 2009.
126. Johnson JJ, Nihal M, Siddiqui IA, Scarlett CO, Bailey HH, Mukhtar H, and Ahmad N. Enhancing the bioavailability of resveratrol by combining it with piperine. Mol Nutr Food Res 55: 1169-1176, 2011.
127. Jung EM, Lim JH, Lee TJ, Park JW, Choi KS, and Kwon TK. Curcumin sensitizes tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis through reactive oxygen species-mediated upregulation of death receptor 5 (DR5). Carcinogenesis 26: 1905-1913, 2005.
128. Jung YH, Heo J, Lee YJ, Kwon TK, and Kim YH. Quercetin enhances TRAIL-induced apoptosis in prostate cancer cells via increased protein stability of death receptor 5. Life Sci 86: 351-357, 2010.
129. Kamat AM, Tharakan ST, Sung B, and Aggarwal BB. Curcumin potentiates the antitumor effects of Bacillus Calmette-Guerin against bladder cancer through the downregulation of NF-kappaB and upregulation of TRAIL receptors. Cancer Res 69: 8958-8966, 2009.
130. Kaminski BM, Steinhilber D, Stein JM, and Ulrich S. Phytochemicals resveratrol and sulforaphane as potential agents for enhancing the anti-tumor activities of conventional cancer therapies. Curr Pharm Biotechnol 13: 137-146, 2012.
131. Kanai M, Yoshimura K, Asada M, Imaizumi A, Suzuki C, Matsumoto S, Nishimura T, Mori Y, Masui T, Kawaguchi Y, Yanagihara K, Yazumi S, Chiba T, Guha S, and Aggarwal BB. A phase I/II study of gemcitabine-based chemotherapy plus curcumin for patients with gemcitabine-resistant pancreatic cancer. Cancer Chemother Pharmacol 68: 157-164, 2011.
132. Kane RC, Farrell AT, Sridhara R, and Pazdur R. United States Food and Drug Administration approval summary: Bortezomib for the treatment of progressive multiple myeloma after one prior therapy. Clin Cancer Res 12: 2955-2960, 2006.
133. Karnak D and Xu L. Chemosensitization of prostate cancer by modulating Bcl-2 family proteins. Curr Drug Targets 11: 699-707, 2010.
134. Karunagaran D, Tzahar E, Beerli RR, Chen X, Graus-Porta D, Ratzkin BJ, Seger R, Hynes NE, and Yarden Y. ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: Implications for breast cancer. EMBO J 15: 254-264, 1996.
135. Katsman A, Umezawa K, and Bonavida B. Chemosensitization and immunosensitization of resistant cancer cells to apoptosis and inhibition of metastasis by the specific NFkappaB inhibitor DHMEQ. Curr Pharm Des 15: 792-808, 2009.
136. Khan SA, Chatterton RT, Michel N, Bryk M, Lee O, Ivancic D, Heinz R, Zalles CM, Helenowski IB, Jovanovic BD, Franke AA, Bosland MC, Wang J, Hansen NM, Bethke KP, Dew A, Coomes M, and Bergan RC. Soy isoflavone supplementation for breast cancer risk reduction: A randomized phase II trial. Cancer Prev Res (Phila) 5: 309-319, 2012.
137. Kim JW, Amin AR, and Shin DM. Chemoprevention of head and neck cancer with green tea polyphenols. Cancer Prev Res (Phila) 3: 900-909, 2010.
138. Kim JY, Kim EH, Park SS, Lim JH, Kwon TK, and Choi KS. Quercetin sensitizes human hepatoma cells to TRAIL-induced apoptosis via Sp1-mediated DR5 up-regulation and proteasome-mediated c-FLIPS down-regulation. J Cell Biochem 105: 1386-1398, 2008.
139. Kim TH, Jiang HH, Youn YS, Park CW, Tak KK, Lee S, Kim H, Jon S, Chen X, and Lee KC. Preparation and characterization of water-soluble albumin-bound curcumin nanoparticles with improved antitumor activity. Int J Pharm 403: 285-291, 2011.
140. Kim YH, Lee DH, Jeong JH, Guo ZS, and Lee YJ. Quercetin augments TRAIL-induced apoptotic death: Involvement of the ERK signal transduction pathway. Biochem Pharmacol 75: 1946-1958, 2008.
141. Kim YH and Lee YJ. TRAIL apoptosis is enhanced by quercetin through Akt dephosphorylation. J Cell Biochem 100: 998-1009, 2007.
142. Kitazono M, Sumizawa T, Takebayashi Y, Chen ZS, Furukawa T, Nagayama S, Tani A, Takao S, Aikou T, and Akiyama S. Multidrug resistance and the lung resistancerelated protein in human colon carcinoma SW-620 cells. J Natl Cancer Inst 91: 1647-1653, 1999.
143. Knuefermann C, Lu Y, Liu B, Jin W, Liang K, Wu L, Schmidt M, Mills GB, Mendelsohn J, and Fan Z. HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells. Oncogene 22: 3205-3212, 2003.
144. Ko JC, Su YJ, Lin ST, Jhan JY, Ciou SC, Cheng CM, Chiu YF, Kuo YH, Tsai MS, and Lin YW. Emodin enhances cisplatininduced cytotoxicity via down-regulation of ERCC1 and inactivation of ERK1/2. Lung Cancer 69: 155-164, 2010.
145. Kohno K, Uchiumi T, Niina I, Wakasugi T, Igarashi T, Momii Y, Yoshida T, Matsuo K, Miyamoto N, and Izumi H. Transcription factors and drug resistance. Eur J Cancer 41: 2577-2586, 2005.
146. Koong AC, Chen EY, and Giaccia AJ. Hypoxia causes the activation of nuclear factor kappa B through the phosphorylation of I kappa B alpha on tyrosine residues. Cancer Res 54: 1425-1430, 1994.
147. Kudo C, Yamakoshi H, Sato A, Ohori H, Ishioka C, Iwabuchi Y, and Shibata H. Novel curcumin analogs, GO-Y030 and GO-Y078, are multi-targeted agents with enhanced abilities for multiple myeloma. Anticancer Res 31: 3719-3726, 2011.
148. Kuhar M, Imran S, and Singh N. Curcumin and quercetin combined with cisplatin to induce apoptosis in human laryngeal carcinoma Hep-2 cells through the mitochondrial pathway. J Cancer Mol 3: 121-128, 2007.
149. Kunnumakkara AB, Diagaradjane P, Anand P, Harikumar KB, Deorukhkar A, Gelovani J, Guha S, Krishnan S, and Aggarwal BB. Curcumin sensitizes human colorectal cancer to capecitabine by modulation of cyclin D1, COX-2, MMP-9, VEGF and CXCR4 expression in an orthotopic mouse model. Int J Cancer 125: 2187-2197, 2009.
150. Kunnumakkara AB, Guha S, Krishnan S, Diagaradjane P, Gelovani J, and Aggarwal BB. Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factor-kappaBregulated gene products. Cancer Res 67: 3853-3861, 2007.
151. Kunos CA, Sill MW, Buekers TE, Walker JL, Schilder JM, Yamada SD, Waggoner SE, Mohiuddin M, and Fracasso PM. Low-dose abdominal radiation as a docetaxel chemosensitizer for recurrent epithelial ovarian cancer: A phase I study of the Gynecologic Oncology Group. Gynecol Oncol 120: 224-228, 2011.
152. Kurahashi N, Sasazuki S, Iwasaki M, Inoue M, and Tsugane S. Green tea consumption and prostate cancer risk in Japanese men: A prospective study. Am J Epidemiol 167: 71-77, 2008.
153. Kurokawa T, He G, and Siddik ZH. Protein kinase inhibitors emodin and dichloro-ribofuranosylbenzimidazole modulate the cellular accumulation and cytotoxicity of cisplatin in a schedule-dependent manner. Cancer Chemother Pharmacol 65: 427-436, 2010.
154. Kwan W, Duncan G, Van Patten C, Liu M, and Lim J. A phase II trial of a soy beverage for subjects without clinical disease with rising prostate-specific antigen after radical radiation for prostate cancer. Nutr Cancer 62: 198-207, 2010.
155. Kweon MH, Adhami VM, Lee JS, and Mukhtar H. Constitutive overexpression of Nrf2-dependent heme oxygenase-1 in A549 cells contributes to resistance to apoptosis induced by epigallocatechin 3-gallate. J Biol Chem 281: 33761-33772, 2006.
156. Kweon SH, Song JH, and Kim TS. Resveratrol-mediated reversal of doxorubicin resistance in acute myeloid leukemia cells via downregulation of MRP1 expression. Biochem Biophys Res Commun 395: 104-110, 2010.
157. la Porte C, Voduc N, Zhang G, Seguin I, Tardiff D, Singhal N, and Cameron DW. Steady-State pharmacokinetics and tolerability of trans-resveratrol 2000mg twice daily with food, quercetin and alcohol (ethanol) in healthy human subjects. Clin Pharmacokinet 49: 449-454, 2010.
158. Lai GH, Zhang Z, and Sirica AE. Celecoxib acts in a cyclooxygenase-2- independent manner and in synergy with emodin to suppress rat cholangiocarcinoma growth in vitro through a mechanism involving enhanced Akt inactivation and increased activation of caspases-9 and -3. Mol Cancer Ther 2: 265-271, 2003.
159. Lambert JD, Hong J, Kim DH, Mishin VM, and Yang CS. Piperine enhances the bioavailability of the tea polyphenol (-) -epigallocatechin-3-gallate in mice. J Nutr 134: 1948-1952, 2004.
160. Landis-Piwowar KR, Milacic V, Chen D, Yang H, Zhao Y, Chan TH, Yan B, and Dou QP. The proteasome as a potential target for novel anticancer drugs and chemosensitizers. Drug Resist Updat 9: 263-273, 2006.
161. Lang M, Henson R, Braconi C, and Patel T. Epigallocatechin-gallate modulates chemotherapy-induced apoptosis in human cholangiocarcinoma cells. Liver Int 29: 670-677, 2009.
162. Lanyi A, Deb D, Seymour RC, Ludes-Meyers JH, Subler MA, and Deb S. ''Gain of function'' phenotype of tumorderived mutant p53 requires the oligomerization/nonsequence-specific nucleic acid-binding domain. Oncogene 16: 3169-3176, 1998.
163. Lau A, Villeneuve NF, Sun Z, Wong PK, and Zhang DD. Dual roles of Nrf2 in cancer. Pharmacol Res 58: 262-270, 2008.
164. Lazarevic B, Boezelijn G, Diep LM, Kvernrod K, Ogren O, Ramberg H, Moen A, Wessel N, Berg RE, Egge-Jacobsen W, Hammarstrom C, Svindland A, Kucuk O, Saatcioglu F, Tasken KA, and Karlsen SJ. Efficacy and safety of short- term genistein intervention in patients with localized prostate cancer prior to radical prostatectomy: A randomized, placebo-controlled, double-blind Phase 2 clinical trial. Nutr Cancer 63: 889-898, 2011.
165. Lee AS. GRP78 induction in cancer: Therapeutic and prognostic implications. Cancer Res 67: 3496-3499, 2007.
166. Lee CK, Park KK, Chung AS, and Chung WY. Ginsenoside Rg3 enhances the chemosensitivity of tumors to cisplatin by reducing the basal level of nuclear factor erythroid 2-related factor 2-mediated heme oxygenase-1/NAD(P)H quinone oxidoreductase-1 and prevents normal tissue damage by scavenging cisplatin-induced intracellular reactive oxygen species. Food Chem Toxicol 50: 2565-2574, 2012.
167. Lehnert M, Mross K, Schueller J, Thuerlimann B, Kroeger N, and Kupper H. Phase II trial of dexverapamil and epirubicin in patients with non-responsive metastatic breast cancer. Br J Cancer 77: 1155-1163, 1998.
168. Lev-Ari S, Strier L, Kazanov D, Madar-Shapiro L, Dvory-Sobol H, Pinchuk I, Marian B, Lichtenberg D, and Arber N. Celecoxib and curcumin synergistically inhibit the growth of colorectal cancer cells. Clin Cancer Res 11: 6738-6744, 2005.
169. Lev-Ari S, Vexler A, Starr A, Ashkenazy-Voghera M, Greif J, Aderka D, and Ben-Yosef R. Curcumin augments gemcitabine cytotoxic effect on pancreatic adenocarcinoma cell lines. Cancer Invest 25: 411-418, 2007.
170. Lev DC, Ruiz M, Mills L, McGary EC, Price JE, and Bar-Eli M. Dacarbazine causes transcriptional up-regulation of interleukin 8 and vascular endothelial growth factor in melanoma cells: A possible escape mechanism from chemotherapy. Mol Cancer Ther 2: 753-763, 2003.
171. Li F, Ambrosini G, Chu EY, Plescia J, Tognin S, Marchisio PC, and Altieri DC. Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 396: 580-584, 1998.
172. Li F and Sethi G. Targeting transcription factor NF-kappaB to overcome chemoresistance and radioresistance in cancer therapy. Biochim Biophys Acta 1805: 167-180, 2010.
173. Li J, Liu P, Mao H, Wanga A, and Zhang X. Emodin sensitizes paclitaxel-resistant human ovarian cancer cells to paclitaxel-induced apoptosis in vitro. Oncol Rep 21: 1605-1610, 2009.
174. Li Y, Ahmed F, Ali S, Philip PA, Kucuk O, and Sarkar FH. Inactivation of nuclear factor kappaB by soy isoflavone genistein contributes to increased apoptosis induced by chemotherapeutic agents in human cancer cells. Cancer Res 65: 6934-6942, 2005.
175. Li Y, Ellis KL, Ali S, El-Rayes BF, Nedeljkovic-Kurepa A, Kucuk O, Philip PA, and Sarkar FH. Apoptosis-inducing effect of chemotherapeutic agents is potentiated by soy isoflavone genistein, a natural inhibitor of NF-kappaB in BxPC-3 pancreatic cancer cell line. Pancreas 28: E90-e95, 2004.
176. Li Y, Kucuk O, Hussain M, Abrams J, Cher ML, and Sarkar FH. Antitumor and antimetastatic activities of docetaxel are enhanced by genistein through regulation of osteoprotegerin/receptor activator of nuclear factor-kappaB (RANK)/RANK ligand/MMP-9 signaling in prostate cancer. Cancer Res 66: 4816-4825, 2006.
177. Liang C, Li H, Shen C, Lai J, Shi Z, Liu B, and Tao HM. Genistein potentiates the anti-cancer effects of gemcitabine in human osteosarcoma via the downregulation of Akt and nuclear factor-kappaB pathway. Anticancer Agents Med Chem 12: 554-563, 2012.
178. Lin C, Yu Y, Zhao HG, Yang A, Yan H, and Cui Y. Combination of quercetin with radiotherapy enhances tumor radiosensitivity in vitro and in vivo. Radiother Oncol 2011 DOI: 10.1016/j.radonc.2011.10.023.
179. Lin CJ, Lee CC, Shih YL, Lin TY, Wang SH, Lin YF, and Shih CM. Resveratrol enhances the therapeutic effect of temozolomide against malignant glioma in vitro and in vivo by inhibiting autophagy. Free Radic BiolMed 52: 377-391, 2012.
180. Lin YG, Kunnumakkara AB, Nair A, Merritt WM, Han LY, Armaiz-Pena GN, Kamat AA, Spannuth WA, Gershenson DM, Lutgendorf SK, Aggarwal BB, and Sood AK. Curcumin inhibits tumor growth and angiogenesis in ovarian carcinoma by targeting the nuclear factor-kappaB pathway. Clin Cancer Res 13: 3423-3430, 2007.
181. Liu B, Edgerton S, Yang X, Kim A, Ordonez-Ercan D, Mason T, Alvarez K, McKimmey C, Liu N, and Thor A. Low-dose dietary phytoestrogen abrogates tamoxifenassociated mammary tumor prevention. Cancer Res 65: 879-886, 2005.
182. Liu JD, Chen SH, Lin CL, Tsai SH, and Liang YC. Inhibition of melanoma growth and metastasis by combination with (-) -epigallocatechin-3-gallate and dacarbazine in mice. J Cell Biochem 83: 631-642, 2001.
183. Llobet D, Eritja N, Encinas M, Llecha N, Yeramian A, Pallares J, Sorolla A, Gonzalez-Tallada FJ, Matias-Guiu X, and Dolcet X. CK2 controls TRAIL and Fas sensitivity by regulating FLIP levels in endometrial carcinoma cells. Oncogene 27: 2513-2524, 2008.
184. Luo T, Wang J, Yin Y, Hua H, Jing J, Sun X, Li M, Zhang Y, and Jiang Y. (-) -Epigallocatechin gallate sensitizes breast cancer cells to paclitaxel in a murine model of breast carcinoma. Breast Cancer Res 12: R8, 2010.
185. Mabuchi S, Ohmichi M, Kimura A, Hisamoto K, Hayakawa J, Nishio Y, Adachi K, Takahashi K, Arimoto-Ishida E, Nakatsuji Y, Tasaka K, and Murata Y. Inhibition of phosphorylation of BAD and Raf-1 by Akt sensitizes human ovarian cancer cells to paclitaxel. J Biol Chem 277: 33490-33500, 2002.
186. Mai Z, Blackburn GL, and Zhou Jr. Genistein sensitizes inhibitory effect of tamoxifen on the growth of estrogen receptor-positive and HER2-overexpressing human breast cancer cells. Mol Carcinog 46: 534-542, 2007.
187. Manju S and Sreenivasan K. Gold nanoparticles generated and stabilized bywater soluble curcumin-polymer conjugate: Blood compatibility evaluation and targeted drug delivery onto cancer cells. J Colloid Interface Sci 368: 144-151, 2012.
188. Mao QQ, Bai Y, Lin YW, Zheng XY, Qin J, Yang K, and Xie LP. Resveratrol confers resistance against taxol via induction of cell cycle arrest in human cancer cell lines. Mol Nutr Food Res 54: 1574-1584, 2010.
189. Masuda M, Suzui M, and Weinstein IB. Effects of epigallocatechin-3- gallate on growth, epidermal growth factor receptor signaling pathways, gene expression, and chemosensitivity in human head and neck squamous cell carcinoma cell lines. Clin Cancer Res 7: 4220-4229, 2001.
190. McConkey DJ and Zhu K. Mechanisms of proteasome inhibitor action and resistance in cancer. Drug Resist Updat 11: 164-179, 2008.
191. McFadyen MC, McLeod HL, Jackson FC, Melvin WT, Doehmer J, and Murray GI. Cytochrome P450 CYP1B1 protein expression: A novel mechanism of anticancer drug resistance. Biochem Pharmacol 62: 207-212, 2001.
192. McLarty J, Bigelow RL, Smith M, Elmajian D, Ankem M, and Cardelli JA. Tea polyphenols decrease serum levels of prostate-specific antigen, hepatocyte growth factor, and vascular endothelial growth factor in prostate cancer patients and inhibit production of hepatocyte growth factor and vascular endothelial growth factor in vitro. Cancer Prev Res (Phila) 2: 673-682, 2009.
193. Mei Y, Wei D, and Liu J. Reversal of cancer multidrug resistance by tea polyphenol in KB cells. J Chemother 15: 260-265, 2003.
194. Mendelsohn J and Baselga J. The EGF receptor family as targets for cancer therapy. Oncogene 19: 6550-6565, 2000.
195. Messing E, Gee JR, Saltzstein DR, Kim K, diSant'Agnese A, Kolesar J, Harris L, Faerber A, Havighurst T, Young JM, Efros M, Getzenberg RH, Wheeler MA, Tangrea J, Parnes H, House M, Busby JE, Hohl R, and Bailey H. A phase 2 cancer chemoprevention biomarker trial of isoflavone G-2535 (genistein) in presurgical bladder cancer patients. Cancer Prev Res (Phila) 5: 621-630, 2012.
196. Mickisch GH, Kossig J, Tschada RK, Keilhauer G, Schlick E, and Alken PM. Circumvention of multidrug resistance mediated by P-170 glycoprotein using calcium antagonists in primary human renal cell carcinoma. Urol Int 47: 118-125, 1991.
197. Milacic V, Banerjee S, Landis-Piwowar KR, Sarkar FH, Majumdar AP, and Dou QP. Curcumin inhibits the proteasome activity in human colon cancer cells in vitro and in vivo. Cancer Res 68: 7283-7292, 2008.
198. Miltyk W, Craciunescu CN, Fischer L, Jeffcoat RA, Koch MA, Lopaczynski W, Mahoney C, Crowell J, Paglieri J, and Zeisel SH. Lack of significant genotoxicity of purified soy isoflavones (genistein, daidzein, and glycitein) in 20 patients with prostate cancer. Am J Clin Nutr 77: 875-882, 2003.
199. Minn AJ, Rudin CM, Boise LH, and Thompson CB. Expression of bcl-xL can confer a multidrug resistance phenotype. Blood 86: 1903-1910, 1995.
200. Mita AC, Mita MM, Nawrocki ST, and Giles FJ. Survivin: key regulator of mitosis and apoptosis and novel target for cancer therapeutics. Clin Cancer Res 14: 5000-5005, 2008.
201. Mittal A, Pate MS, Wylie RC, Tollefsbol TO, and Katiyar SK. EGCG down-regulates telomerase in human breast carcinoma MCF-7 cells, leading to suppression of cell viability and induction of apoptosis. Int J Oncol 24: 703-710, 2004.
202. Mohammad RM, Al-Katib A, Aboukameel A, Doerge DR, Sarkar F, and Kucuk O. Genistein sensitizes diffuse large cell lymphoma to CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) chemotherapy. Mol Cancer Ther 2: 1361-1368, 2003.
203. Monti E and Gariboldi MB. HIF-1 as a target for cancer chemotherapy, chemosensitization and chemoprevention. Curr Mol Pharmacol 4: 62-77, 2011.
204. Morgan MJ and Liu ZG. Crosstalk of reactive oxygen species and NF-kappaB signaling. Cell Res 21: 103-115, 2011.
205. Morishita N, Tsukahara H, Chayama K, Ishida T, Washio K, Miyamura T, Yamashita N, Oda M, and Morishima T. Activation of Akt is associated with poor prognosis and chemotherapeutic resistance in pediatric B-precursor acute lymphoblastic leukemia. Pediatr Blood Cancer 59: 83-89, 2012.
206. Morrow DM, Fitzsimmons PE, Chopra M, and McGlynn H. Dietary supplementation with the anti-tumour promoter quercetin: Its effects on matrix metalloproteinase gene regulation. Mutat Res 480-481: 269-276, 2001.
207. Mosieniak G, Adamowicz M, Alster O, Jaskowiak H, Szczepankiewicz AA, Wilczynski GM, Ciechomska IA, and Sikora E. Curcumin induces permanent growth arrest of human colon cancer cells: Link between senescence and autophagy. Mech Ageing Dev 133: 444-455, 2012.
208. Motyl T, Gajkowska B, Zarzynska J, Gajewska M, and Lamparska-Przybysz M. Apoptosis and autophagy in mammary gland remodeling and breast cancer chemotherapy. J Physiol Pharmacol 57 Suppl 7: 17-32, 2006.
209. Mulholland PJ, Ferry DR, Anderson D, Hussain SA, Young AM, Cook JE, Hodgkin E, Seymour LW, and Kerr DJ. Preclinical and clinical study of QC12, a water-soluble, prodrug of quercetin. Ann Oncol 12: 245-248, 2001.
210. Nair KL, Thulasidasan AK, Deepa G, Anto RJ, and Kumar GS. Purely aqueous PLGA nanoparticulate formulations of curcumin exhibit enhanced anticancer activity with dependence on the combination of the carrier. Int J Pharm 425: 44-52, 2012.
211. Nakamura Y, Yogosawa S, Izutani Y, Watanabe H, Otsuji E, and Sakai T. A combination of indol-3-carbinol and genistein synergistically induces apoptosis in human colon cancer HT-29 cells by inhibiting Akt phosphorylation and progression of autophagy. Mol Cancer 8: 100, 2009.
212. Nambiar D, Rajamani P, and Singh RP. Effects of phytochemicals on ionization radiation-mediated carcinogenesis and cancer therapy. Mutat Res 728: 139-157, 2011.
213. Nguyen AV, Martinez M, Stamos MJ, Moyer MP, Planutis K, Hope C, and Holcombe RF. Results of a phase I pilot clinical trial examining the effect of plant-derived resveratrol and grape powder on Wnt pathway target gene expression in colonic mucosa and colon cancer. Cancer Manag Res 1: 25-37, 2009.
214. Nihal M, Ahsan H, Siddiqui IA, Mukhtar H, Ahmad N, and Wood GS. (-) -Epigallocatechin-3-gallate (EGCG) sensitizes melanoma cells to interferon induced growth inhibition in a mouse model of human melanoma. Cell Cycle 8: 2057-2063, 2009.
215. Nishida N, Yamashita S, Mimori K, Sudo T, Tanaka F, Shibata K, Yamamoto H, Ishii H, Doki Y, and Mori M. MicroRNA-10b is a prognostic indicator in colorectal cancer and confers resistance to the chemotherapeutic agent 5-fluorouracil in colorectal cancer cells. Ann Surg Oncol 19: 3065-3071, 2012.
216. Nishikawa T, Nakajima T, Moriguchi M, Jo M, Sekoguchi S, Ishii M, Takashima H, Katagishi T, Kimura H, Minami M, Itoh Y, Kagawa K, and Okanoue T. A green tea polyphenol, epigalocatechin-3-gallate, induces apoptosis of human hepatocellular carcinoma, possibly through inhibition of Bcl-2 family proteins. J Hepatol 44: 1074-1082, 2006.
217. Niture SK, Kaspar JW, Shen J, and Jaiswal AK. Nrf2 signaling and cell survival. Toxicol Appl Pharmacol 244: 37-42, 2010.
218. Notarbartolo M, Poma P, Perri D, Dusonchet L, Cervello M, and D'Alessandro N. Antitumor effects of curcumin, alone or in combination with cisplatin or doxorubicin, on human hepatic cancer cells. Analysis of their possible relationship to changes in NF-kB activation levels and in IAP gene expression. Cancer Lett 224: 53-65, 2005.
219. Ohnuma T, Matsumoto T, Itoi A, Kawana A, Nishiyama T, Ogura K, and Hiratsuka A. Enhanced sensitivity of A549 cells to the cytotoxic action of anticancer drugs via suppression of Nrf2 by procyanidins from Cinnamomi Cortex extract. Biochem Biophys Res Commun 413: 623-629, 2011.
220. Orlowski RZ. Bortezomib in combination with other therapies for the treatment of multiple myeloma. J Natl Compr Canc Netw 2 Suppl 4: S16-S20, 2004.
221. Parikh SA, Kantarjian H, Schimmer A, Walsh W, Asatiani E, El-Shami K, Winton E, and Verstovsek S. Phase II study of obatoclax mesylate (GX15-070), a small-molecule BCL-2 family antagonist, for patients with myelofibrosis. Clin Lymphoma Myeloma Leuk 10: 285-289, 2010.
222. Park SY and Seol DW. Regulation of Akt by EGF-R inhibitors, a possible mechanism of EGF-R inhibitor-enhanced TRAIL-induced apoptosis. Biochem Biophys Res Commun 295: 515-518, 2002.
223. Patel BB, Sengupta R, Qazi S, Vachhani H, Yu Y, Rishi AK, and Majumdar AP. Curcumin enhances the effects of 5-fluorouracil and oxaliplatin in mediating growth inhibition of colon cancer cells by modulating EGFR and IGF-1R. Int J Cancer 122: 267-273, 2008.
224. Patel KR, Brown VA, Jones DJ, Britton RG, Hemingway D, Miller AS, West KP, Booth TD, Perloff M, Crowell JA, Brenner DE, Steward WP, Gescher AJ, and Brown K. Clinical pharmacology of resveratrol and its metabolites in colorectal cancer patients. Cancer Res 70: 7392-7399, 2010.
225. Pendleton JM, Tan WW, Anai S, Chang M, Hou W, Shiverick KT, and Rosser CJ. Phase II trial of isoflavone in prostate-specific antigen recurrent prostate cancer after previous local therapy. BMC Cancer 8: 132, 2008.
226. Perez RP. Cellular and molecular determinants of cisplatin resistance. Eur J Cancer 34: 1535-1542, 1998.
227. Pervaiz S and Clement MV. Tumor intracellular redox status and drug resistance - serendipity or a causal relationship? Curr Pharm Des 10: 1969-1977, 2004.
228. Ping SY, Hour TC, Lin SR, and Yu DS. Taxol synergizes with antioxidants in inhibiting hormal refractory prostate cancer cell growth. Urol Oncol 28: 170-179, 2010.
229. Pisters KM, Newman RA, Coldman B, Shin DM, Khuri FR, Hong WK, Glisson BS, and Lee JS. Phase I trial of oral green tea extract in adult patients with solid tumors. J Clin Oncol 19: 1830-1838, 2001.
230. Pommier Y, Sordet O, Antony S, Hayward RL, and Kohn KW. Apoptosis defects and chemotherapy resistance: Molecular interaction maps and networks. Oncogene 23: 2934-2949, 2004.
231. Psahoulia FH, Drosopoulos KG, Doubravska L, Andera L, and Pintzas A. Quercetin enhances TRAIL-mediated apoptosis in colon cancer cells by inducing the accumulation of death receptors in lipid rafts. Mol Cancer Ther 6: 2591-2599, 2007.
232. Pyrko P, Schonthal AH, Hofman FM, Chen TC, and Lee AS. The unfolded protein response regulator GRP78/BiP as a novel target for increasing chemosensitivity in malignant gliomas. Cancer Res 67: 9809-9816, 2007.
233. Qian F, Wei D, Zhang Q, and Yang S. Modulation of Pglycoprotein function and reversal of multidrug resistance by (-) -epigallocatechin gallate in human cancer cells. Biomed Pharmacother 59: 64-69, 2005.
234. Qian H, Yang Y, and Wang X. Curcumin enhanced adriamycin-induced human liver-derived Hepatoma G2 cell death through activation of mitochondria-mediated apoptosis and autophagy. Eur J Pharm Sci 43: 125-131, 2011.
235. Quan F, Pan C, Ma Q, Zhang S, and Yan L. Reversal effect of resveratrol on multidrug resistance in KBv200 cell line. Biomed Pharmacother 62: 622-629, 2008.
236. Radovic J, Maksimovic-Ivanic D, Timotijevic G, Popadic S, Ramic Z, Trajkovic V, Miljkovic D, Stosic-Grujicic S, and Mijatovic S. Cell-type dependent response of melanoma cells to aloe emodin. Food Chem Toxicol 50: 3181-3189, 2012.
237. Rai B, Kaur J, Jacobs R, and Singh J. Possible action mechanism for curcumin in pre-cancerous lesions based on serum and salivary markers of oxidative stress. J Oral Sci 52: 251-256, 2010.
238. Ravi R and Bedi A. Sensitization of tumor cells to Apo2 ligand/TRAIL-induced apoptosis by inhibition of casein kinase II. Cancer Res 62: 4180-4185, 2002.
239. Reddy RK, Mao C, Baumeister P, Austin RC, Kaufman RJ, and Lee AS. Endoplasmic reticulum chaperone protein GRP78 protects cells from apoptosis induced by topoisomerase inhibitors: Role of ATP binding site in suppression of caspase-7 activation. J Biol Chem 278: 20915-20924, 2003.
240. Ren D, Villeneuve NF, Jiang T, Wu T, Lau A, Toppin HA, and Zhang DD. Brusatol enhances the efficacy of chemotherapy by inhibiting the Nrf2-mediated defense mechanism. Proc Natl Acad Sci U S A 108: 1433-1438, 2011.
241. Rezk YA, Balulad SS, Keller RS, and Bennett JA. Use of resveratrol to improve the effectiveness of cisplatin and doxorubicin: study in human gynecologic cancer cell lines and in rodent heart. Am J Obstet Gynecol 194: E23-e26, 2006.
242. Ricci MS, Kim SH, Ogi K, Plastaras JP, Ling J, Wang W, Jin Z, Liu YY, Dicker DT, Chiao PJ, Flaherty KT, Smith CD, and El-Deiry WS. Reduction of TRAIL-induced Mcl-1 and cIAP2 by c-Myc or sorafenib sensitizes resistant human cancer cells to TRAIL-induced death. Cancer Cell 12: 66-80, 2007.
243. Rieger PT. Interferon-alpha: A clinical update. Cancer Pract 3: 356-365, 1995.
244. Rigolio R, Miloso M, Nicolini G, Villa D, Scuteri A, Simone M, and Tredici G. Resveratrol interference with the cell cycle protects human neuroblastoma SH-SY5Y cell from paclitaxel-induced apoptosis. Neurochem Int 46: 205-211, 2005.
245. Russo M, Nigro P, Rosiello R, D'Arienzo R, and Russo GL. Quercetin enhances CD95- and TRAIL-induced apoptosis in leukemia cell lines. Leukemia 21: 1130-1133, 2007.
246. Russo M, Palumbo R, Mupo A, Tosto M, Iacomino G, Scognamiglio A, Tedesco I, Galano G, and Russo GL. Flavonoid quercetin sensitizes a CD95-resistant cell line to apoptosis by activating protein kinase Calpha. Oncogene 22: 3330-3342, 2003.
247. Sadava D, Whitlock E, and Kane SE. The green tea polyphenol, epigallocatechin-3-gallate inhibits telomerase and induces apoptosis in drug-resistant lung cancer cells. Biochem Biophys Res Commun 360: 233-237, 2007.
248. Sakon S, Xue X, Takekawa M, Sasazuki T, Okazaki T, Kojima Y, Piao JH, Yagita H, Okumura K, Doi T, and Nakano H. NF-kappaB inhibits TNF-induced accumulation of ROS that mediate prolonged MAPK activation and necrotic cell death. EMBO J 22: 3898-3909, 2003.
249. Sallman DA, Chen X, Zhong B, Gilvary DL, Zhou J, Wei S, and Djeu JY. Clusterin mediates TRAIL resistance in prostate tumor cells. Mol Cancer Ther 6: 2938-2947, 2007.
250. Sato M, Yao VJ, Arap W, and Pasqualini R. GRP78 signaling hub a receptor for targeted tumor therapy. Adv Genet 69: 97-114, 2010.
251. Satoh H, Nishikawa K, Suzuki K, Asano R, Virgona N, Ichikawa T, Hagiwara K, and Yano T. Genistein, a soy isoflavone, enhances necrotic-like cell death in a breast cancer cell treated with a chemotherapeutic agent. Res Commun Mol Pathol Pharmacol 113-114: 149-158, 2003.
252. Scandlyn MJ, Stuart EC, Somers-Edgar TJ, Menzies AR, and Rosengren RJ. A new role for tamoxifen in oestrogen receptor-negative breast cancer when it is combined with epigallocatechin gallate. Br J Cancer 99: 1056-1063, 2008.
253. Scarlatti F, Sala G, Ricci C, Maioli C, Milani F, Minella M, Botturi M, and Ghidoni R. Resveratrol sensitization of DU145 prostate cancer cells to ionizing radiation is associated to ceramide increase. Cancer Lett 253: 124-130, 2007.
254. Shanafelt TD, Call TG, Zent CS, LaPlant B, Bowen DA, Roos M, Secreto CR, Ghosh AK, Kabat BF, Lee MJ, Yang CS, Jelinek DF, Erlichman C, and Kay NE. Phase I trial of daily oral Polyphenon E in patients with asymptomatic Rai stage 0 to II chronic lymphocytic leukemia. J Clin Oncol 27: 3808-3814, 2009.
255. Shanafelt TD, Lee YK, Call TG, Nowakowski GS, Dingli D, Zent CS, and Kay NE. Clinical effects of oral green tea extracts in four patients with low grade B-cell malignancies. Leuk Res 30: 707-712, 2006.
256. Shankar S, Chen Q, Siddiqui I, Sarva K, and Srivastava RK. Sensitization of TRAIL-resistant LNCaP cells by resveratrol (3, 4¢, 5 tri-hydroxystilbene): Molecular mechanisms and therapeutic potential. J Mol Signal 2: 7, 2007.
257. Shankar S, Ganapathy S, Chen Q, and Srivastava RK. Curcumin sensitizes TRAIL-resistant xenografts: Molecular mechanisms of apoptosis, metastasis and angiogenesis. Mol Cancer 7: 16, 2008.
258. Sharma RA, Euden SA, Platton SL, Cooke DN, Shafayat A, Hewitt HR, Marczylo TH, Morgan B, Hemingway D, Plummer SM, Pirmohamed M, Gescher AJ, and Steward WP. Phase I clinical trial of oral curcumin: Biomarkers of systemic activity and compliance. Clin Cancer Res 10: 6847-6854, 2004.
259. Sharma RA, McLelland HR, Hill KA, Ireson CR, Euden SA, Manson MM, Pirmohamed M, Marnett LJ, Gescher AJ, and Steward WP. Pharmacodynamic and pharmacokinetic study of oral Curcuma extract in patients with colorectal cancer. Clin Cancer Res 7: 1894-1900, 2001.
260. Shehzad A, Wahid F, and Lee YS. Curcumin in cancer chemoprevention: Molecular targets, pharmacokinetics, bioavailability, and clinical trials. Arch Pharm (Weinheim) 343: 489-499, 2010.
261. Shen J, Hughes C, Chao C, Cai J, Bartels C, Gessner T, and Subjeck J. Coinduction of glucose-regulated proteins and doxorubicin resistance in Chinese hamster cells. Proc Natl Acad Sci U S A 84: 3278-3282, 1987.
262. Shen J, Tai YC, Zhou J, Stephen Wong CH, Cheang PT, Fred Wong WS, Xie Z, Khan M, Han JH, and Chen CS. Synergistic antileukemia effect of genistein and chemotherapy in mouse xenograft model and potential mechanism through MAPK signaling. Exp Hematol 35: 75-83, 2007.
263. Shen M, Chan TH, and Dou QP. Targeting tumor ubiquitinproteasome pathway with polyphenols for chemosensitization. Anticancer Agents Med Chem 12: 891-901, 2012.
264. Shen Q, Tian F, Jiang P, Li Y, Zhang L, Lu J, and Li J. EGCG enhances TRAIL-mediated apoptosis in human melanoma A375 cell line. J Huazhong Univ Sci Technolog Med Sci 29: 771-775, 2009.
265. Shervington A, Pawar V, Menon S, Thakkar D, and Patel R. The sensitization of glioma cells to cisplatin and tamoxifen by the use of catechin. Mol Biol Rep 36: 1181-1186, 2009.
266. Shimizu M, Deguchi A, Lim JT, Moriwaki H, Kopelovich L, and Weinstein IB. (-) -Epigallocatechin gallate and polyphenon E inhibit growth and activation of the epidermal growth factor receptor and human epidermal growth factor receptor-2 signaling pathways in human colon cancer cells. Clin Cancer Res 11: 2735-2746, 2005.
267. Shoba G, Joy D, Joseph T, Majeed M, Rajendran R, and Srinivas PS. Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta Med 64: 353-356, 1998.
268. Si HY, Li DP, Wang TM, Zhang HL, Ren FY, Xu ZG, and Zhao YY. Improving the anti-tumor effect of genistein with a biocompatible superparamagnetic drug delivery system. J Nanosci Nanotechnol 10: 2325-2331, 2010.
269. Siddiqui IA, Adhami VM, Bharali DJ, Hafeez BB, Asim M, Khwaja SI, Ahmad N, Cui H, Mousa SA, and Mukhtar H. Introducing nanochemoprevention as a novel approach for cancer control: proof of principle with green tea polyphenol epigallocatechin-3-gallate. Cancer Res 69: 1712-1716, 2009.
270. Siddiqui IA, Malik A, Adhami VM, Asim M, Hafeez BB, Sarfaraz S, and Mukhtar H. Green tea polyphenol EGCG sensitizes human prostate carcinoma LNCaP cells to TRAIL-mediated apoptosis and synergistically inhibits biomarkers associated with angiogenesis and metastasis. Oncogene 27: 2055-2063, 2008.
271. Siegelin MD, Habel A, and Gaiser T. Epigalocatechin-3-gallate (EGCG) downregulates PEA15 and thereby augments TRAIL-mediated apoptosis in malignant glioma. Neurosci Lett 448: 161-165, 2008.
272. Siegelin MD, Reuss DE, Habel A, Rami A, and von Deimling A. Quercetin promotes degradation of survivin and thereby enhances death-receptor-mediated apoptosis in glioma cells. Neuro Oncol 11: 122-131, 2009.
273. Siegelin MD, Siegelin Y, Habel A, and Gaiser T. Genistein enhances proteasomal degradation of the short isoform of FLIP in malignant glioma cells and thereby augments TRAIL-mediated apoptosis. Neurosci Lett 453: 92-97, 2009.
274. Singhal A, Jain H, Singhal V, Elias EJ, and Showkat A. Colon-targeted quercetin delivery using natural polymer to enhance its bioavailability. Pharmacognosy Res 3: 35-39, 2011.
275. Sirichanchuen B, Pengsuparp T, and Chanvorachote P. Long-term cisplatin exposure impairs autophagy and causes cisplatin resistance in human lung cancer cells. Mol Cell Biochem 364: 11-18, 2012.
276. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, and Norton L. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344: 783-792, 2001.
277. Sleijfer S, Bannink M, Van Gool AR, Kruit WH, and Stoter G. Side effects of interferon-alpha therapy. Pharm World Sci 27: 423-431, 2005.
278. Smith AJ, Kavuru P, Wojtas L, Zaworotko MJ, and Shytle RD. Cocrystals of quercetin with improved solubility and oral bioavailability. Mol Pharm 8: 1867-1876, 2011.
279. Smith CD and Zilfou JT. Circumvention of P-glycoproteinmediated multiple drug resistance by phosphorylation modulators is independent of protein kinases. J Biol Chem 270: 28145-28152, 1995.
280. Somasundaram S, Edmund NA, Moore DT, Small GW, Shi YY, and Orlowski RZ. Dietary curcumin inhibits chemotherapy-induced apoptosis in models of human breast cancer. Cancer Res 62: 3868-3875, 2002.
281. Song X, Liu X, Chi W, Liu Y, Wei L, Wang X, and Yu J. Hypoxia-induced resistance to cisplatin and doxorubicin in non-small cell lung cancer is inhibited by silencing of HIF-1alpha gene. Cancer Chemother Pharmacol 58: 776-784, 2006.
282. Song Z, Feng R, Sun M, Guo C, Gao Y, Li L, and Zhai G. Curcumin-loaded PLGA-PEG-PLGA triblock copolymeric micelles: Preparation, pharmacokinetics and distribution in vivo. J Colloid Interface Sci 354: 116-123, 2011.
283. Souza PS, Vasconcelos FC, De Souza Reis FR, Nestal De Moraes G, and Maia RC. P-glycoprotein and survivin simultaneously regulate vincristine-induced apoptosis in chronic myeloid leukemia cells. Int J Oncol 39: 925-933, 2011.
284. Sreekanth CN, Bava SV, Sreekumar E, and Anto RJ. Molecular evidences for the chemosensitizing efficacy of liposomal curcumin in paclitaxel chemotherapy in mouse models of cervical cancer. Oncogene 30: 3139-3152, 2011.
285. Su YJ, Tsai MS, Kuo YH, Chiu YF, Cheng CM, Lin ST, and Lin YW. Role of Rad51 down-regulation and extracellular signal-regulated kinases 1 and 2 inactivation in emodin and mitomycin C-induced synergistic cytotoxicity in human non-small-cell lung cancer cells. Mol Pharmacol 77: 633-643, 2010.
286. Subbaramaiah K, Hart JC, Norton L, and Dannenberg AJ. Microtubule-interfering agents stimulate the transcription of cyclooxygenase-2. Evidence for involvement of ERK1/2 AND p38 mitogen-activated protein kinase pathways. J Biol Chem 275: 14838-14845, 2000.
287. Suganuma M, Kurusu M, Suzuki K, Tasaki E, and Fujiki H. Green tea polyphenol stimulates cancer preventive effects of celecoxib in human lung cancer cells by upregulation of GADD153 gene. Int J Cancer 119: 33-40, 2006.
288. Suganuma M, Okabe S, Kai Y, Sueoka N, Sueoka E, and Fujiki H. Synergistic effects of (-) -epigallocatechin gallate with (-) -epicatechin, sulindac, or tamoxifen on cancerpreventive activity in the human lung cancer cell line PC-9. Cancer Res 59: 44-47, 1999.
289. Swain SM, Lippman ME, Egan EF, Drake JC, Steinberg SM, and Allegra CJ. Fluorouracil and high-dose leucovorin in previously treated patients with metastatic breast cancer. J Clin Oncol 7: 890-899, 1989.
290. Szliszka E, Czuba ZP, Jernas K, and Krol W. Dietary flavonoids sensitize HeLa cells to tumor necrosis factorrelated apoptosis-inducing ligand (TRAIL). Int J Mol Sci 9: 56-64, 2008.
291. Tan L, Kwok RP, Shukla A, Kshirsagar M, Zhao L, Opipari AW, Jr., and Liu Jr. Trichostatin A restores Apaf-1 function in chemoresistant ovarian cancer cells. Cancer 117: 784-794, 2011.
292. Tang H, Murphy CJ, Zhang B, Shen Y, Van Kirk EA, Murdoch WJ, and Radosz M. Curcumin polymers as anticancer conjugates. Biomaterials 31: 7139-7149, 2010.
293. Tang J, Xu N, Ji H, Liu H, Wang Z, and Wu L. Eudragit nanoparticles containing genistein: formulation, development, and bioavailability assessment. Int J Nanomed 6: 2429-2435, 2011.
294. Tang X, Wang H, Fan L, Wu X, Xin A, Ren H, and Wang XJ. Luteolin inhibits Nrf2 leading to negative regulation of the Nrf2/ARE pathway and sensitization of human lung carcinoma A549 cells to therapeutic drugs. Free Radic Biol Med 50: 1599-1609, 2011.
295. Taniguchi T, Tischkowitz M, Ameziane N, Hodgson SV, Mathew CG, Joenje H, Mok SC, and D'Andrea AD. Disruption of the Fanconi anemia-BRCA pathway in cisplatinsensitive ovarian tumors. Nat Med 9: 568-574, 2003.
296. Thallinger C, Wolschek MF, Wacheck V, Maierhofer H, Gunsberg P, Polterauer P, Pehamberger H, Monia BP, Selzer E, Wolff K, and Jansen B. Mcl-1 antisense therapy chemosensitizes human melanoma in a SCID mouse xenotransplantation model. J Invest Dermatol 120: 1081-1086, 2003.
297. Thangasamy T, Sittadjody S, Limesand KH, and Burd R. Tyrosinase overexpression promotes ATM-dependent p53 phosphorylation by quercetin and sensitizes melanoma cells to dacarbazine. Cell Oncol 30: 371-387, 2008.
298. Thangasamy T, Sittadjody S, Mitchell GC, Mendoza EE, Radhakrishnan VM, Limesand KH, and Burd R. Quercetin abrogates chemoresistance in melanoma cells by modulating deltaNp73. BMC Cancer 10: 282, 2010.
299. Tonino SH, van Laar J, van Oers MH, Wang JY, Eldering E, and Kater AP. ROS-mediated upregulation of Noxa overcomes chemoresistance in chronic lymphocytic leukemia. Oncogene 30: 701-713, 2011.
300. Ugurel S, Rappl G, Tilgen W, and Reinhold U. Increased soluble CD95 (sFas/CD95) serum level correlates with poor prognosis in melanoma patients. Clin Cancer Res 7: 1282-1286, 2001.
301. Vaishampayan U, Hussain M, Banerjee M, Seren S, Sarkar FH, Fontana J, Forman JD, Cher ML, Powell I, Pontes JE, and Kucuk O. Lycopene and soy isoflavones in the treatment of prostate cancer. Nutr Cancer 59: 1-7, 2007.
302. van Uden P, Kenneth NS, and Rocha S. Regulation of hypoxia-inducible factor-1alpha by NF-kappaB. Biochem J 412: 477-484, 2008.
303. Villalona-Calero MA, Otterson GA, Wientjes MG, Weber F, Bekaii-Saab T, Young D, Murgo AJ, Jensen R, Yeh TK, Wei Y, Zhang Y, Eng C, Grever M, and Au JL. Noncytotoxic suramin as a chemosensitizer in patients with advanced non-small-cell lung cancer: A phase II study. Ann Oncol 19: 1903-1909, 2008.
304. Vinall RL, Hwa K, Ghosh P, Pan CX, Lara PN, Jr., and de Vere White RW. Combination treatment of prostate cancer cell lines with bioactive soy isoflavones and perifosine causes increased growth arrest and/or apoptosis. Clin Cancer Res 13: 6204-6216, 2007.
305. Wang J, Yin Y, Hua H, Li M, Luo T, Xu L, Wang R, Liu D, Zhang Y, and Jiang Y. Blockade of GRP78 sensitizes breast cancer cells to microtubules-interfering agents that induce the unfolded protein response. J Cell Mol Med 13: 3888-3897, 2009.
306. Wang L, Lee IM, Zhang SM, Blumberg JB, Buring JE, and Sesso HD. Dietary intake of selected flavonols, flavones, and flavonoid-rich foods and risk of cancer in middle-aged and older women. Am J Clin Nutr 89: 905-912, 2009.
307. Wang P, Aronson WJ, Huang M, Zhang Y, Lee RP, Heber D, and Henning SM. Green tea polyphenols and metabolites in prostatectomy tissue: Implications for cancer prevention. Cancer Prev Res (Phila) 3: 985-993, 2010.
308. Wang Q and Wieder R. All-trans retinoic acid potentiates Taxotere-induced cell death mediated by Jun N-terminal kinase in breast cancer cells. Oncogene 23: 426-433, 2004.
309. Wang S, Chen T, Chen R, Hu Y, Chen M, and Wang Y. Emodin loaded solid lipid nanoparticles: preparation, characterization and antitumor activity studies. Int J Pharm 430: 238-246, 2012.
310. Wang W, McLeod HL, Cassidy J, and Collie-Duguid ES. Mechanisms of acquired chemoresistance to 5-fluorouracil and tomudex: Thymidylate synthase dependent and independent networks. Cancer Chemother Pharmacol 59: 839-845, 2007.
311. Wang W, Sun YP, Huang XZ, He M, Chen YY, Shi GY, Li H, Yi J, and Wang J. Emodin enhances sensitivity of gallbladder cancer cells to platinum drugs via glutathion depletion and MRP1 downregulation. Biochem Pharmacol 79: 1134-1140, 2010.
312. Wei D, Mei Y, and Liu J. Quantification of doxorubicin and validation of reversal effect of tea polyphenols on multidrug resistance in human carcinoma cells. Biotechnol Lett 25: 291-294, 2003.
313. Weller M, Malipiero U, Aguzzi A, Reed JC, and Fontana A. Protooncogene bcl-2 gene transfer abrogates Fas/APO-1 antibody-mediated apoptosis of human malignant glioma cells and confers resistance to chemotherapeutic drugs and therapeutic irradiation. J Clin Invest 95: 2633-2643, 1995.
314. Xie X, Tao Q, Zou Y, Zhang F, Guo M, Wang Y, Wang H, Zhou Q, and Yu S. PLGA nanoparticles improve the oral bioavailability of curcumin in rats: Characterizations and mechanisms. J Agric Food Chem 59: 9280-9289, 2011.
315. Xing H, Weng D, Chen G, Tao W, Zhu T, Yang X, Meng L, Wang S, Lu Y, and Ma D. Activation of fibronectin/PI-3K/Akt2 leads to chemoresistance to docetaxel by regulating survivin protein expression in ovarian and breast cancer cells. Cancer Lett 261: 108-119, 2008.
316. Xu X, Chen K, Kobayashi S, Timm D, and Liang Q. Resveratrol attenuates doxorubicin-induced cardiomyocyte death via inhibition of p70 S6 kinase 1-mediated autophagy. J Pharmacol Exp Ther 341: 183-195, 2012.
317. Yamamoto T, Staples J, Wataha J, Lewis J, Lockwood P, Schoenlein P, Rao S, Osaki T, Dickinson D, Kamatani T, Schuster G, and Hsu S. Protective effects of EGCG on salivary gland cells treated with gamma-radiation or cisplatinum(II)diammine dichloride. Anticancer Res 24: 3065-3073, 2004.
318. Yamauchi Y, Izumi Y, Asakura K, Hayashi Y, and Nomori H. Curcumin Induces Autophagy in ACC-MESO-1 Cells. Phytother Res 2012 [Epub ahead of print]; Doi: 10.1002/ptr.4645.
319. Yan M, Myung SJ, Fink SP, Lawrence E, Lutterbaugh J, Yang P, Zhou X, Liu D, Rerko RM, Willis J, Dawson D, Tai HH, Barnholtz-Sloan JS, Newman RA, Bertagnolli MM, and Markowitz SD. 15-Hydroxyprostaglandin dehydrogenase inactivation as a mechanism of resistance to celecoxib chemoprevention of colon tumors. Proc Natl Acad Sci U S A 106: 9409-9413, 2009.
320. Yang J, Li H, Chen YY, Wang XJ, Shi GY, Hu QS, Kang XL, Lu Y, Tang XM, Guo QS, and Yi J. Anthraquinones sensitize tumor cells to arsenic cytotoxicity in vitro and in vivo via reactive oxygen species-mediated dual regulation of apoptosis. Free Radic Biol Med 37: 2027-2041, 2004.
321. Yap WN, Zaiden N, Luk SY, Lee DT, Ling MT, Wong YC, and Yap YL. In vivo evidence of gamma-tocotrienol as a chemosensitizer in the treatment of hormone-refractory prostate cancer. Pharmacology 85: 248-258, 2010.
322. Yi J, Yang J, He R, Gao F, Sang H, Tang X, and Ye RD. Emodin enhances arsenic trioxide-induced apoptosis via generation of reactive oxygen species and inhibition of survival signaling. Cancer Res 64: 108-116, 2004.
323. Young LC, Campling BG, Cole SP, Deeley RG, and Gerlach JH. Multidrug resistance proteins MRP3, MRP1, and MRP2 in lung cancer: Correlation of protein levels with drug response and messenger RNA levels. Clin Cancer Res 7: 1798-1804, 2001.
324. Yu D, Liu B, Tan M, Li J, Wang SS, and Hung MC. Overexpression of c-erbB-2/neu in breast cancer cells confers increased resistance to Taxol via mdr-1-independent mechanisms. Oncogene 13: 1359-1365, 1996.
325. Zhang B, Shi ZL, Liu B, Yan XB, Feng J, and Tao HM. Enhanced anticancer effect of gemcitabine by genistein in osteosarcoma: The role of Akt and nuclear factor-kappaB. Anticancer Drugs 21: 288-296, 2010.
326. Zhang H, Li B, Bai SW, and Wang HJ. Constitutively active Akt contributes to vincristine resistance in human retinoblastoma cells. Cancer Invest 28: 156-165, 2010.
327. Zhang K, Mack P, and Wong KP. Glutathione-related mechanisms in cellular resistance to anticancer drugs. Int J Oncol 12: 871-882, 1998.
328. Zhang L, Chang CJ, Bacus SS, and Hung MC. Suppressed transformation and induced differentiation of HER-2/neuoverexpressing breast cancer cells by emodin. Cancer Res 55: 3890-3896, 1995.
329. Zhang L and Hung MC. Sensitization of HER-2/neuoverexpressing non-small cell lung cancer cells to chemotherapeutic drugs by tyrosine kinase inhibitor emodin. Oncogene 12: 571-576, 1996.
330. Zhang L, Lau YK, Xia W, Hortobagyi GN, and Hung MC. Tyrosine kinase inhibitor emodin suppresses growth of HER-2/neu-overexpressing breast cancer cells in athymic mice and sensitizes these cells to the inhibitory effect of paclitaxel. Clin Cancer Res 5: 343-353, 1999.
331. Zhang Q, Wei D, and Liu J. In vivo reversal of doxorubicin resistance by (-) -epigallocatechin gallate in a solid human carcinoma xenograft. Cancer Lett 208: 179-186, 2004.
332. Zhang X, Jin TG, Yang H, DeWolf WC, Khosravi-Far R, and Olumi AF. Persistent c-FLIP(L) expression is necessary and sufficient to maintain resistance to tumor necrosis factorrelated apoptosis-inducing ligand-mediated apoptosis in prostate cancer. Cancer Res 64: 7086-7091, 2004.
333. Zhang XM, Chen J, Xia YG, and Xu Q. Apoptosis of murine melanoma B16-BL6 cells induced by quercetin targeting mitochondria, inhibiting expression of PKC-alpha and translocating PKC-delta. Cancer Chemother Pharmacol 55: 251-262, 2005.
334. Zhou BB and Bartek J. Targeting the checkpoint kinases: Chemosensitization versus chemoprotection. Nat Rev Cancer 4: 216-225, 2004.
335. Zhou S, Zhao L, Kuang M, Zhang B, Liang Z, Yi T, Wei Y, and Zhao X. Autophagy in tumorigenesis and cancer therapy: Dr. Jekyll or Mr. Hyde? Cancer Lett 323: 115-127, 2012.
336. Zhu A, Wang X, and Guo Z. Study of tea polyphenol as a reversal agent for carcinoma cell lines' multidrug resistance (study of TP as a MDR reversal agent). Nucl Med Biol 28: 735-740, 2001.